Ipswich Investment Management Co. Inc. Has $254,000 Stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Ipswich Investment Management Co. Inc. trimmed its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,255 shares of the company’s stock after selling 153 shares during the period. Ipswich Investment Management Co. Inc.’s holdings in GE HealthCare Technologies were worth $254,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. LGT Financial Advisors LLC lifted its holdings in shares of GE HealthCare Technologies by 1,673.3% in the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after acquiring an additional 251 shares during the last quarter. Capital Performance Advisors LLP bought a new position in shares of GE HealthCare Technologies in the third quarter worth about $26,000. Ashton Thomas Securities LLC bought a new position in shares of GE HealthCare Technologies in the third quarter worth about $26,000. Darwin Wealth Management LLC bought a new position in shares of GE HealthCare Technologies in the third quarter worth about $31,000. Finally, Continuum Advisory LLC lifted its holdings in shares of GE HealthCare Technologies by 101.8% in the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after acquiring an additional 168 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on GEHC shares. Citigroup increased their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. Finally, Wells Fargo & Company raised their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $97.67.

GE HealthCare Technologies Stock Down 1.1 %

GE HealthCare Technologies stock opened at $91.09 on Friday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80. The firm has a 50 day moving average price of $85.05 and a two-hundred day moving average price of $85.83. The firm has a market cap of $41.66 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 3.20 and a beta of 1.15.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The firm had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. Equities analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.